Ovarian minimal residual disease in chronic myeloid leukaemia Ronit Abir, Adina Aviram, Meora Feinmesser, Jerry Stein, Isaac Yaniv, Doris Parnes, Avi Ben-Haroush, Dror Meirow, Esther Rabizadeh, Benjamin Fisch  Reproductive BioMedicine Online  Volume 28, Issue 2, Pages 255-260 (February 2014) DOI: 10.1016/j.rbmo.2013.10.011 Copyright © 2013 Reproductive Healthcare Ltd. Terms and Conditions

Figure 1 Quantitative reverse-transcription PCR for ABL (A) and BCR-ABL (B) detection. Typical fluorescence curves obtained for standards (dotted lines) and sample (unbroken lines). Reproductive BioMedicine Online 2014 28, 255-260DOI: (10.1016/j.rbmo.2013.10.011) Copyright © 2013 Reproductive Healthcare Ltd. Terms and Conditions

Figure 2 Two-step nested quantitative reverse-transcription PCR. PCR products were analysed on a 2% agarose gel. Sample lanes 1–4=cryopreserved ovarian tissue sample with a PCR product of 458bp, typical for b3a2 transcripts (the breakpoint of BCR gene is downstream of exon 14); NEG=Philadelphia-negative sample derived from healthy control; NTC=no-template control; POS=Philadelphia-positive sample derived from a CML patient with a PCR product of 383bp, typical for b2a2 transcripts (the breakpoint of BCR gene is downstream of exon 13); ABL=positive control for the gene ABL, demonstrating RNA integrity of the sample); Marker=100-bp DNA size ladder. Reproductive BioMedicine Online 2014 28, 255-260DOI: (10.1016/j.rbmo.2013.10.011) Copyright © 2013 Reproductive Healthcare Ltd. Terms and Conditions